Myriad Genetics, Inc. (MYGN): Price and Financial Metrics

MYGN POWR Grades

• MYGN scores best on the Value dimension, with a Value rank ahead of 68.45% of US stocks.
• The strongest trend for MYGN is in Momentum, which has been heading down over the past 52 weeks.
• MYGN ranks lowest in Momentum; there it ranks in the 10th percentile.

MYGN Stock Summary

• The ratio of debt to operating expenses for Myriad Genetics Inc is higher than it is for about merely 24.1% of US stocks.
• MYGN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 26.02% of US stocks.
• With a year-over-year growth in debt of -31.92%, Myriad Genetics Inc's debt growth rate surpasses merely 16.45% of about US stocks.
• If you're looking for stocks that are quantitatively similar to Myriad Genetics Inc, a group of peers worth examining would be CCF, PMD, OFIX, SSD, and LNN.
• MYGN's SEC filings can be seen here. And to visit Myriad Genetics Inc's official web site, go to myriad.com.

MYGN Valuation Summary

• MYGN's price/sales ratio is 4.2; this is 10.53% higher than that of the median Healthcare stock.
• MYGN's price/sales ratio has moved down 18.4 over the prior 243 months.
• Over the past 243 months, MYGN's price/earnings ratio has gone up 101.3.

Below are key valuation metrics over time for MYGN.

MYGN Growth Metrics

• Its 3 year price growth rate is now at -20.45%.
• Its 3 year net income to common stockholders growth rate is now at -85.86%.
• Its 5 year net income to common stockholders growth rate is now at -252.75%.

Over the past 49 months, MYGN's revenue has gone down $109,100,000.

The table below shows MYGN's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	662.3	-6.3	-97.3
2021-03-31	566.1	28.1	-148
2020-12-31	557	-26.9	-223.7
2020-09-30	597.5	-14.4	-194.1
2020-06-30	638.6	60.7	-199.5
2020-03-31	760.8	62.2	-148.3

MYGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• MYGN has a Quality Grade of C, ranking ahead of 60.73% of graded US stocks.
• MYGN's asset turnover comes in at 0.476 -- ranking 96th of 681 Pharmaceutical Products stocks.
• CDXC, CEMI, and GERN are the stocks whose asset turnover ratios are most correlated with MYGN.

The table below shows MYGN's key quality metrics over time.